MedTrace Logo

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2026-05-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

Conditions

  • Small Cell Lung Carcinoma
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • Neuroendocrine Prostate Cancer
  • Gastroenteropancreatic Neuroendocrine Carcinoma

Interventions

DRUG

225Ac-ETN029

Radioligand therapy

DRUG

111In-ETN029

Radioligand imaging agent

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-16
Primary Completion
2031-08-29
Completion
2031-08-29
FDA Drug
Yes

Countries

  • United States
  • Canada
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07006727 on ClinicalTrials.gov